Literature DB >> 7821302

Risk factors for acquisition of multiply drug-resistant gram-negative bacteria.

I M Gould1.   

Abstract

Some bacteria are naturally resistant to many antibiotics and most can become multiply resistant. Multiply resistant gram-negative bacteria have proved a particular problem over the last 30 years, but the development of new agents has lessened their significance for most clinicians. Now, however, clinical practice is threatened by the lack of new classes of antibiotics, the widespread emergence of resistance and the advent of plasmid-mediated cephalosporinases by which the spread of resistance is likely to be rapid. Increased use of prophylaxis in immunosuppressed and intensive care patients is likely to aggravate the problem, as is the use of new broad-spectrum agents in the community. More directed and restricted antibiotic use and better education of patients and prescriber are necessary to contain the problem of antibiotic resistance. Improved surveillance of sensitivity trends is essential. Many outbreaks also are associated with poor infection control techniques. The cost of outbreaks due to multiply resistant organisms and lack of compliance with infection control procedures needs to be properly studied. While many predisposing factors for the acquisition of these organisms and the development of infection are understood, the multifactorial nature of illness in many patients complicates the issue, necessitating further study of risk factors and preventative and therapeutic measures.

Entities:  

Mesh:

Year:  1994        PMID: 7821302     DOI: 10.1007/bf02390682

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  60 in total

1.  Superinfections by Escherichia coli resistant to fluoroquinolones in immunocompromised patients.

Authors:  N Somolinos; R Arranz; M C Del Rey; M L Jiménez
Journal:  J Antimicrob Chemother       Date:  1992-11       Impact factor: 5.790

2.  Global surveillance of antibiotic resistance.

Authors:  T F O'Brien
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

3.  Changes in the spectrum of organisms causing bacteremia and fungemia in immunocompromised patients due to venous access devices.

Authors:  T E Kiehn; D Armstrong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

4.  Current prophylaxis for prevention of infective endocarditis.

Authors:  I M Gould
Journal:  Br Dent J       Date:  1990-05-19       Impact factor: 1.626

5.  Antibiotic dispensing by drug store personnel in Bangkok, Thailand.

Authors:  V Thamlikitkul
Journal:  J Antimicrob Chemother       Date:  1988-01       Impact factor: 5.790

6.  A seven year survey of antibiotic susceptibility and its relationship with usage.

Authors:  R J Courcol; M Pinkas; G R Martin
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

7.  Ethical considerations in the use of subliminal stimulation to improve handwashing compliance: scientific utility versus autonomy of the individual.

Authors:  M B Edmond; R P Wenzel
Journal:  Infect Control Hosp Epidemiol       Date:  1993-02       Impact factor: 3.254

Review 8.  Epidemiology and control of nosocomial infections in adult intensive care units.

Authors:  R A Weinstein
Journal:  Am J Med       Date:  1991-09-16       Impact factor: 4.965

9.  Acquisition of endemic Pseudomonas aeruginosa on an intensive therapy unit.

Authors:  K D Allen; C A Bartzokas; R Graham; M F Gibson; A A Gilbertson
Journal:  J Hosp Infect       Date:  1987-09       Impact factor: 3.926

Review 10.  beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.

Authors:  C C Sanders; W E Sanders
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

View more
  3 in total

1.  Molecular epidemiology of ceftazidime-resistant gram-negative bacilli on inanimate surfaces and their role in cross-transmission during nonoutbreak periods.

Authors:  E M D'Agata; L Venkataraman; P DeGirolami; M Samore
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

Authors:  Valerie Aloush; Shiri Navon-Venezia; Yardena Seigman-Igra; Shaltiel Cabili; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

Review 3.  Current guidelines for the treatment and prevention of nosocomial infections.

Authors:  E Bergogne-Bérézin
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.